IP Library › Granted Patent US 12,281,329
Granted Patent B2
US 12,281,329 · App. 17/369,831 · Granted Apr 22, 2025

Compositions and methods for immune cell modulation in adoptive immunotherapies

Inventors: Jonathan Rosen (San Diego, CA); Betsy Rezner (San Diego, CA); Bahram Valamehr (San Diego, CA); Ryan Bjordahl (San Diego, CA); Eigen Peralta (San Diego, CA)
Assignee: FATE THERAPEUTICS, INC.
C12N5/0646A61K31/436A61K31/506A61K31/7084A61K31/7105A61K31/713A61K39/4613A61K39/464406A61K39/464424A61K45/06A61P31/00A61P35/00A61P37/06C12N5/0636G01N33/505A61K38/2086A61K2239/38A61K2239/48A61K2239/55A61K2239/59C12N2501/06C12N2501/2312C12N2501/2318C12N2501/25C12N2501/727C12N2501/999C12N2503/02Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,329
App. No.
17/369,831
Granted
Apr 22, 2025
Kind
B2
Abstract

Compounds that either produced a higher proportion or greater absolute number of phenotypically identified nave, stem cell memory, central memory T cells, adaptive NK cells, and type I NKT cells are identified. Compositions and methods for modulating immune cells including T, NK, and NKT cells for adoptive cell therapies with improved efficacy are provided.

Claims (50)

1. A composition comprising immune cells, and at least one agent, wherein:

(a) the immune cells comprise a population of modulated immune cells that are modulated by the at least one agent;

(b) the population of modulated immune cells have improved therapeutic potential in comparison to unmodulated immune cells that are not modulated by the at least one agent;

(c) the at least one agent comprises a GSK3 Inhibitor;

(d) the immune cells are genetically modified to comprise an insertion, a deletion, or a nucleic acid replacement; and

(e) the modulated immune cells comprise NK cells.

2. The composition of claim 1 , wherein the population of modulated immune cells comprises cells that have:

i. improved proliferation, cytotoxicity, cytokine response, cytokine release, cell recall, and/or persistence;

ii. improved cell expansion, maintenance, differentiation, dedifferentiation, and/or survival rate; and/or

iii. increased number or ratio of one or more desired subpopulations of immune cells, in comparison to immune cells not contacted with said at least one agent.

3. The composition of claim 2 , wherein the population of modulated immune cells or the one or more desired immune cell subpopulations having increased number or ratio, comprise:

i. CD57 + NK cells, or adaptive NK cells;

ii. adaptive NK cells comprising CD57 + and at least one of NKG2C + , low PLZF, low SYK, low FcεRγ, low EAT-2, low TIGIT, low PD1, low CD7, low CD161, high LILRB1, high CD45RO, and low CD45RA; or

iii. CD57 + NK cells expressing hnCD16.

4. A composition comprising isolated immune cells, wherein the isolated immune cells comprise the one or more desired subpopulations of immune cells isolated from the composition of claim 2 .

5. The composition of claim 1 , wherein the immune cells (a) are differentiated in vitro from stem cells, hematopoietic stem or progenitor cells; or (b) are trans-differentiated in vitro from non-pluripotent cells of hematopoietic or non-hematopoietic lineage.

6. The composition of claim 5 , wherein the immune cells are differentiated from stem cells, and wherein the stem cells comprise induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs).

7. The composition of claim 5 , wherein the immune cells are differentiated from progenitor cells, and wherein the progenitor cells comprise CD34 + hemogenic endothelium cells, multipotent progenitor cells, or NK progenitor cells.

8. The composition of claim 7 , wherein the progenitor cells comprise the insertion, deletion, or nucleic acid replacement.

9. The composition of claim 1 , wherein the modulated immune cells comprise CD57 − NK cells or CD57 − NKG2C + NK cells.

10. The composition of claim 9 , wherein the NK cells:

i. have increased expression in one or more of CD107a, NKG2C, NKG2D, CD16, KIR, CD2, NKp30, NKp44 and NKp46, in comparison to unmodulated NK cells, wherein the expression thereof is increased by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% or above;

ii. have increased expansion by at least 2 fold; and/or

iii. have improved cytokine response comprising increased production of one or more cytokines comprising IFNγ and/or TNFα.

11. The composition of claim 1 , wherein the immune cells are isolated from: (1) a healthy subject; (2) a subject having an autoimmune disease, a hematopoietic malignancy, a virus infection or a solid tumor; (3) a subject previously administered with genetically modified immune cells; or (4) a subject that is CMV seropositive.

12. The composition of claim 1 , wherein the immune cells are isolated from or comprised in peripheral blood, bone marrow lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.

13. The composition of claim 1 , wherein the composition is feeder-free.

14. The composition of claim 1 , wherein the immune cells are activated.

15. The composition of claim 1 , wherein CD3 and CD19 cells are depleted from the immune cells.

16. The composition of claim 1 , wherein the immune cells are genetically modified to comprise at least one of safety switch proteins, targeting modalities, receptors, signaling molecules, transcription factors, pharmaceutically active proteins and peptides; or proteins promoting engraftment, trafficking, homing, viability, self-renewal, persistence, immune response regulation and modulation, or survival of the immune cells.

17. The composition of claim 1 , wherein the immune cells are genetically modified to comprise one or more of:

(a) deletion or reduced expression of B2M, TAP1, TAP2, Tapasin, NLRC5, PD1, LAG3, TIM3, RFXANK, CIITA, RFX5, or RFXAP, and any gene in the chromosome 6p21 region; or

(b) introduced or increased expression of HLA-E, HLA-G, CD16, hnCD16, 4-1BBL, CD3, CD4, CD8, CD47, CD113, CD131, CD137, CD80, PDL1, A2AR, Fc receptor, or surface triggering receptors for coupling with bi- or multi-specific or universal engagers.

18. The composition of claim 1 , wherein the immune cells are cells that have been in contact with the at least one agent for no less than 16 hours.

19. The composition of claim 1 , wherein the composition further comprises one or more of a TGFβ receptor inhibitor, a ROCK inhibitor, a MEK inhibitor, a PDK1 agonist, and rapamycin.

20. The composition of claim 19 , wherein the composition comprises:

(i) CHIR99021;

(ii) the GSK3 inhibitor and IL15;

(iii) the GSK3 inhibitor, IL15, and a STING agonist; or

(iv) at least one organic solvent selected from the group consisting of dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), dimethoxyethane (DME), dimethylacetamide, ethanol and combinations thereof.

21. The composition of claim 1 , wherein the composition further comprises one or more additives.

22. The composition of claim 21 , wherein the one or more additives comprise:

(a) at least one of peptides, antibodies, antibody fragments, cytokines, mitogens, growth factors, small RNAs, dsRNA, mononuclear blood cells, feeder cells, feeder cell components or replacement factors, vectors comprising one or more polynucleic acids of interest, chemotherapeutic agents or radioactive moieties, and immunomodulatory drugs (IMiDs);

(b) at least one of stimulating cytokines comprising IL2, IL15, IL12, IL18 and IL21; or

(c) one or more of a MEK inhibitor, rapamycin, and a STING agonist.

23. The composition of claim 22 , wherein the antibodies or antibody fragments comprise anti-CD20 antibodies, anti-Her2 antibodies, anti-CD52 antibodies, anti-EGFR antibodies, anti-CD38 antibodies, or humanized or Fc modified variants thereof.

24. The composition of claim 23 , wherein the antibodies or antibody fragments are selected from the group consisting of: retuximab, veltuzumab, ofatumumab, ublituximab, ocaratuzumab, obinutuzumab, trastuzumab, alemtuzumab, certuximab, and daratumumab.

25. The composition of claim 22 , wherein the chemotherapeutic agents comprise anthracycline, an alkylating agent, an alkyl sulfonate, an aziridine, an ethylenimine, a methylmelamine, a nitrogen mustard, a nitrosourea, an antibiotic, an antimetabolite, a folic acid analog, a purine analog, a pyrimidine analog, an enzyme, a podophyllotoxin, a platinum-containing agent, an interferon, or an interleukin.

26. The composition of claim 22 , wherein the IMiDs are selected from thalidomide, lenalidomide, and pomalidomide.

27. The composition of claim 1 , further comprising T cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2022
From: ROSEN, JONATHAN; REZNER, BETSY; VALAMEHR, BAHRAM; BJORDAHL, RYAN; PERALTA, EIGEN
To: FATE THERAPEUTICS, INC.
Reel/Frame 059749/0528 →
Continuity (4)
Division 16071457
Provisional Application 62336339 · May 13, 2016
Provisional Application 62281064 · Jan 20, 2016
Related Publication 20210393695A1 · Dec 23, 2021
References Cited (131)
US 8044201B2 · Xu et al. · 2011 [cited by applicant]
US 9233125B2 · Davila · 2016 [cited by examiner]
US 9376664B2 · Efe et al. · 2016 [cited by applicant]
US 9556417B2 · Efe et al. · 2017 [cited by applicant]
US 9828399B2 · Tremblay · 2017 [cited by examiner]
US 11096964B2 · Rosen et al. · 2021 [cited by applicant]
US 11413309B2 · Rosen et al. · 2022 [cited by applicant]
US 11859003B2 · Luo · 2024 [cited by examiner]
US 11932870B2 · Rosen et al. · 2024 [cited by applicant]
US 20010053361A1 · Thompson et al. · 2001 [cited by applicant]
US 20040175373A1 · Berenson et al. · 2004 [cited by applicant]
US 20050075276A1 · Rudd · 2005 [cited by applicant]
US 20060247214A1 · DeLong et al. · 2006 [cited by applicant]
US 20160009813A1 · Themeli et al. · 2016 [cited by applicant]
US 20170296659A1 · Lebwohl et al. · 2017 [cited by applicant]
US 20180072992A1 · Valamehr et al. · 2018 [cited by applicant]
US 20180243341A1 · June et al. · 2018 [cited by applicant]
US 20180320137A1 · Valamehr et al. · 2018 [cited by applicant]
US 20190125795A1 · Rosen et al. · 2019 [cited by applicant]
US 20190282618A1 · Rosen et al. · 2019 [cited by applicant]
US 20200181573A1 · Rosen et al. · 2020 [cited by applicant]
US 20220401487A1 · Rosen et al. · 2022 [cited by applicant]
CN 102027105A · 2011 [cited by applicant]
EP 2303319A2 · 2011 [cited by applicant]
EP 2638896A1 · 2012 [cited by applicant]
GB 2444853A · 2008 [cited by applicant]
GB 2444853B · 2008 [cited by applicant]
JP 2019502725A · 2019 [cited by applicant]
WO WO9901426A1 · 1999 [cited by applicant]
WO WO0112596A1 · 2001 [cited by applicant]
WO WO0206213A2 · 2002 [cited by applicant]
WO WO0206213A3 · 2002 [cited by applicant]
WO WO03077914A1 · 2003 [cited by applicant]
WO WO2005051301A2 · 2005 [cited by applicant]
WO WO2005051301A3 · 2005 [cited by applicant]
WO WO2007044084A2 · 2007 [cited by applicant]
WO WO2007044084A3 · 2007 [cited by applicant]
WO WO2007103901A2 · 2007 [cited by applicant]
WO WO2007103901A3 · 2007 [cited by applicant]
WO WO2008006583A1 · 2008 [cited by applicant]
WO WO2009117439A2 · 2009 [cited by applicant]
WO WO2009155535A2 · 2009 [cited by applicant]
WO WO2010083298A1 · 2010 [cited by applicant]
WO WO2015155738A2 · 2015 [cited by applicant]
WO WO2015155738A3 · 2015 [cited by applicant]
WO WO2015160986A2 · 2015 [cited by applicant]
WO WO2015160986A3 · 2015 [cited by applicant]
WO WO2015188119A1 · 2015 [cited by applicant]
WO WO2016040892A1 · 2016 [cited by applicant]
WO WO2016123100A1 · 2016 [cited by applicant]
WO WO2016123117A1 · 2016 [cited by applicant]
WO WO2016160621A2 · 2016 [cited by applicant]
WO WO2016160621A3 · 2016 [cited by applicant]
WO WO2016179283A1 · 2016 [cited by applicant]
WO WO2016187158A1 · 2016 [cited by applicant]
WO WO2017078807A1 · 2017 [cited by applicant]
WO WO2017078807A9 · 2017 [cited by applicant]
WO WO2017127729A1 · 2017 [cited by applicant]
WO WO2017127755A1 · 2017 [cited by applicant]
WO WO2018231951A1 · 2018 [cited by applicant]
Soriani, et al. (2013) “Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma”, Oncolmmunology, 2:12, e26663 (3 pages). (Year: 2013). [cited by examiner]
Barbey et al., “Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid,” [cited by applicant]
Chan et al., “Conformational Control Inhibition of the BCR-ABL 1 Tyrosine Kinase, Including the Gatekeeper T3151 Mutant, by the Switch-Control Inhibitor DCC-2036,” [cited by applicant]
Garcillán et al., “γδ T lymphocytes in the diagnosis of human t cell receptor immunodeficiencies,” [cited by applicant]
Mestermann et al., “The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CART cells,” [cited by applicant]
Mustjoki et al., “Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy,” [cited by applicant]
Parameswaran et al., “Novel Approach for NK Cell Therapy for Cancer,” [cited by applicant]
Seggewiss et al., “Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner,” [cited by applicant]
Tighe et al., “GSK-3 inhibitors induce chromosome instability,” [cited by applicant]
Weichsel et al., “Profound Inhibition of Antigen-SpecificT-Cell Effector Functions by Dasatinib.,” [cited by applicant]
Wu et al., “Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment,” [cited by applicant]
Yoshioka et al., “Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation,” [cited by applicant]
Parameswaran et al., “Repression of GSK3 restores NK cell cytotoxicity in AML patients,” [cited by applicant]
Araki, K. et al. (Jul. 2, 2009, e-published Jun. 21, 2009). “mTOR regulates memory CD8 T-cell differentiation,” [cited by applicant]
Chang, C.H. et al. (Jun. 6, 2013). “Posttranscriptional control of T cell effector function by aerobic glycolysis,” [cited by applicant]
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase Ib Study of PROHEMA(R) (Feb. 26, 2014). located at <http://ir.fatetherapeutics.com/releasedetail.cfm?releasei… [cited by applicant]
Goessling, W. et al. (Apr. 8, 2011). “Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models,” [cited by applicant]
Nerreter et al., “Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro,” [cited by applicant]
Nikiforow et al., “Evolution of T Cell Repertoire Diversity After Reduced-Intensity Conditioning and Double Umbilical Cord Blood Transplantation with or without Exposure to FT1050 (16,16-dimethyl Prostaglandin E2)” [cited by applicant]
Roskoski et al., “Properties of FDA-approved small molecule protein kinase inhibitors,” [cited by applicant]
Rossari et al., “Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy,” [cited by applicant]
Rutishauser, R.L. et al. (Aug. 21, 2009, e-published Aug. 6, 2009). “Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties,” [cited by applicant]
Schwarzbich et al., “The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors,” [cited by applicant]
Sukumar, M. et al. (Oct. 2013, Sep. 16, 2013). “Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function,” [cited by applicant]
Wolleschak et al., “FLT3-Kinase Inhibitors Quizartinib and Midostaurin Do Not Impair T-Cell Reactivity and Activation,” [cited by applicant]
Wu et al., “Rapamycin Promotes Expansion of CD4+CD25+FOXP3+Regulatory T Cells by Modulating Fatty Acid Metabolism,” [cited by applicant]
Zhang, J.Y. et al. (Jan. 10, 2018). “Modulation of CD8 + memory stem T cell activity and glycogen synthase kinase 3β inhibition enhances anti-tumoral immunity in gastric cancer,” [cited by applicant]
Zhou, X. et al. (Sep. 15, 2012, e-published Aug. 8, 2012). “Cutting edge: generation of memory precursors and functional memory CD8+ T cells depends on T cell factor-1 and lymphoid enhancer-binding factor-1,” [cited by applicant]
Aoukaty, A. et al. (Apr. 15, 2005). “Role for glycogen synthase kinase-3 in NK cell cytotoxicity and X-linked lymphoproliferative disease,” [cited by applicant]
Araki, K. et al. (May 2010). “The role of mTOR in memory CD8 T-cell differentiation,” [cited by applicant]
Asanuma, S. et al. (Jun. 2011, e-published Nov. 24, 2010). “Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin,” [cited by applicant]
Battaglia, M. et al. (Jun. 15, 2005, e-published Mar. 3, 2005). “Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells,” [cited by applicant]
Berger, C. et al (Jan. 2008). “Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates,” [cited by applicant]
Cao et al., “Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells,” [cited by applicant]
Cheng, M. et al. (May 2013, e-published Apr. 22, 2013). “NK cell-based immunotherapy for malignant diseases,” [cited by applicant]
Esteban, M.A. et al. (Jan. 8, 2010, e-published Dec. 31, 2009). “Vitamin C enhances the generation of mouse and human induced pluripotent stem cells,” [cited by applicant]
Extended European Search Report mailed Oct. 2, 2019, for EP Patent Application No. 17742046.0, 12 pages. [cited by applicant]
Feng, B. et al. (Apr. 3, 2009). “Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells,” [cited by applicant]
Fujisaki, H. et al. (May 1, 2009, e-published Apr. 21, 2009). “Expansion of highly cytotoxic human natural killer cells for cancer cell therapy,” Cancer Res 69(9):4010-4017. [cited by applicant]
Goldman et al., “Immunology Overview,” [cited by applicant]
Huangfu, D et al. (Jul. 2008, e-published Jun. 22, 2008). “Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds,” [cited by applicant]
Huangfu, D et al. (Nov. 2008, e-published Oct. 12, 2008). “Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2,” [cited by applicant]
Ichida, J.K. et al. (Nov. 6, 2009, e-published Oct. 8, 2009). “A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog,” [cited by applicant]
Inman, G.J. et al. (Jul. 2002). “SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7,” [cited by applicant]
International Search Report mailed on Apr. 18, 2017 for PCT/US2017/014408, filed Jan. 20, 2017, 5 pages. [cited by applicant]
Kim, D. et al. (Jun. 5, 2009, e-published May 28, 2009). “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,” Cell Stem Cell 4(6):472-476. [cited by applicant]
Kim, G.G. et al. (Aug. 31, 2007, e-published Jun. 28, 2007). “A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay,” [cited by applicant]
King, C.C. et al. (Jun. 16, 2000). “Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1,” [cited by applicant]
Liu, Y. et al. (Jan. 2015, e-published Jul. 14, 2014). “mTOR signaling in T cell immunity and autoimmunity,” [cited by applicant]
Lyssiotis, C.A. et al. (Jun. 2, 2009, e-published May 15, 2009). “Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4,” PNAS [cited by applicant]
Mack et al., “Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors,” [cited by applicant]
Maherali, N. et al. (Nov. 3, 2009, e-published Sep. 17, 2009). “Tgfβ signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc,” [cited by applicant]
Partial Supplementary European Search Report mailed on Jun. 24, 2019, for EP Patent Application No. 17742046.0, 13 pages. [cited by applicant]
Perkins, M.R. et al. (Dec. 3, 2015). “Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA Car T Cells,” [cited by applicant]
Robson et al., “Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling,” [cited by applicant]
Rosen, J. et al. (Dec. 2, 2016). “Identification of small molecule modulators to enhance the therapeutic properties of chimeric antigen receptor T cells,” [cited by applicant]
Saha, K. et al. (Dec. 4, 2009). “Technical challenges in using human induced pluripotent stem cells to model disease,” Cell Stem Cell 5(6):584-595. [cited by applicant]
Shi, Y. et al. (Jun. 5, 2008). “A combined chemical and genetic approach for the generation of induced pluripotent stem cells,” [cited by applicant]
Shi, Y. et al. (Nov. 6, 2008). “Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds,” [cited by applicant]
Silva, J. et al. (Oct. 21, 2008). “Promotion of reprogramming to ground state pluripotency by signal inhibition,” [cited by applicant]
Sommermeyer, D. et al. (Feb. 2016, e-published Sep. 15, 2015). “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo,” [cited by applicant]
Takahashi, K. et al. (Aug. 25, 2006, e-published Aug. 10, 2006). “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,” [cited by applicant]
Takahashi, K. et al. (Nov. 30, 2007). “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” [cited by applicant]
Wai, L-E. et al. (Jan. 15, 2008). “Rapamycin, but not cyclosporine or FK506, alters natural killer cell function,” [cited by applicant]
Written Opinion mailed on Apr. 18, 2017 for PCT/US2017/014408, filed Jan. 20, 2017, 5 pages. [cited by applicant]
Yamanaka, S. et al. (Jul. 2, 2009). “Elite and stochastic models for induced pluripotent stem cell generation,” [cited by applicant]
Yu, J. et al. (Dec. 21, 2007, e-published Nov. 20, 2007). “Induced pluripotent stem cell lines derived from human somatic cells,” [cited by applicant]
Zhou, H. et al. (May 8, 2009, e-published Apr. 23, 2009). “Generation of induced pluripotent stem cells using recombinant proteins,” [cited by applicant]
Baker et al., “Prostaglandin inhibition of T-cell proliferation is mediated at two levels,” [cited by applicant]
Kalinski, “Regulation of immune responses by prostaglandin E2,” [cited by applicant]
Sakata et al., “Prostaglandin E2, an immunoactivator,” [cited by applicant]